MYH11–LMOD1 Axis Promotes Ferroptosis and Inhibits Migration and Invasion in Non–Small‐Cell Lung Cancer
The Journal of Gene Medicine · 2026-11 · 28 (11)
DOI: 10.1002/jgm.70118 ↗Abstract
ABSTRACT Background Ferroptosis has emerged as a critical mechanism influencing the development of non–small‐cell lung cancer (NSCLC). Emerging evidence implicates the dysregulation of leiomodin 1 (LMOD1) in tumorigenesis. This work explored in detail the function of LMOD1 in NSCLC ferroptosis and malignant progression. Methods The expression pattern of LMOD1 in NSCLC was analyzed using GSE238161, GSE229301, and the GEPIA platform. Analysis of correlation between LMOD1 and immune cell infiltration was performed using the TIMER algorithm. LMOD1‐associated genes were identified using LinkedOmics platform and subjected to KEGG pathway enrichment analysis. The effects of LMOD1 were evaluated by detecting cell colony formation, migration, and invasion. The impact on ferroptosis was assessed by measuring ROS levels and related protein expression. The myosin heavy chain 11 (MYH11)–LMOD1 relationship was confirmed by chromatin immunoprecipitation (ChIP) and luciferase assays. Results LMOD1 expression was downregulated in NSCLC and correlated with tumor TNM stage and lymph node metastasis. Bioinformatics analysis suggested a potential correlation between LMOD1 expression and immune cell infiltration in NSCLC. LMOD1 might intersect with multiple signaling pathways, including PI3K–Akt, MAPK, calcium, cGMP–PKG, Th1/Th2 differentiation, and chemokine signaling. Functionally, increase of LMOD1 suppressed cell growth, migration, and invasion while enhancing ferroptosis. Mechanistically, MYH11 acted as a transcriptional activator of LMOD1 by binding to the LMOD1 promoter region. Conclusion Our study shows that LMOD1, transcriptionally activated by MYH11, functions as a tumor suppressor in NSCLC by enhancing ferroptosis, uncovering a previously unrecognized therapeutic strategy for NSCLC intervention.
EUVIMED